Adaptive immune receptor

The term adaptive immune receptors refers to the antigen-recognition molecules of the adaptive immune system, including B cell receptors (BCRs, membrane-bound immunoglobulins) and T cell receptors (TCRs). These receptors are expressed on B and T lymphocytes and are fundamental to the highly specific, versatile, and memory-forming immune responses characteristic of adaptive immunity. They are generated by gene rearrangement processes (V(D)J recombination and somatic hypermutation), resulting in enormous diversity, allowing the recognition of millions of different antigens[1][6][8]. Upon binding their cognate antigen, these receptors trigger lymphocyte activation, leading to immune memory (with memory B/T cells), antibody secretion, cytokine release, and cytotoxic responses. Malfunctions can result in autoimmunity, allergy, or immunodeficiency[4][7]. Therapeutically, individual receptors (such as TCRs in engineered cell therapies, and BCRs in monoclonal antibody technology) are targeted or harnessed for cancer, infectious, and autoimmune diseases. The term itself is a collective label for this family, and not a single, druggable molecular entity. No drugs directly target "adaptive immune receptors" as a group; drugs such as monoclonal antibodies, checkpoint inhibitors, and TCR-mediated immunotherapies target or utilize specific receptors. There is no unified mechanism of action for the entire class; for specific members: activation, blockade, modulation, or engineering for therapy. There is no widely used canonical abbreviation for the class, although specific receptors like "T cell receptor" use "TCR" and "B cell receptor" uses "BCR". There is no universal biomarker for the whole class, though specific biomarkers exist for individual components.

Other names

Adaptive immunity receptorsAntigen receptors of adaptive immunityImmunoglobulin receptor (for B cells)T cell receptorB cell receptor